• Health and wellness CBD-based probiotics distributor HempFusion Wellness, Inc. recently announced an agreement to acquire CBD brand pioneer Apothecanna’s holding company
• The deal will give HempFusion an additional 1,800 retail outlets for its brand, notably in CVS stores, to supplement the 4,000 retail locations HempFusion already uses in all 50 states
• Apothecanna’s sales revenues during 2020 were more than $4 million — double HempFusion’s historical revenue
• HempFusion also recently announced that a multi-billion-dollar customer in Dubai, United Arab Emirates, has revived its product purchases after more than a year’s pause in international sales during the pandemic

Health and wellness supplement innovator HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) is expanding its footprint in retail outlets while celebrating the revival of international sales for its cannabidiol (“CBD”) lines. HempFusion has established itself as a scientifically formulated probiotic product retailer that relies on hemp to help specific consumer demographics achieve total gut health support and skin care. On May 17, the company announced it has entered a purchase agreement that will allow it to acquire 100 percent interest in APCNA Holdings LLC, the holdings company that owns the Apothecanna CBD line (https://ibn.fm/vRUtS). Apothecanna is a CBD brand that is distributed in 1,800 stores nationwide through CVS and 7th Sense outlets, as well as others. The opportunity for HempFusion’s brand to increase its distribution by nearly 2,000 stores is augmented by Apothecanna’s strategic business relationship that gives it significant market share in the Canadian topicals space. Apothecanna pioneered cannabis-powered body care and topicals and was the first topicals brand to expand nationally and obtain a federal trademark, according to the news release. Last year it had revenues of over $4 million, which is double HempFusion’s historical revenue and the company has plans to continue expanding during 2021. “We are incredibly excited to enter into this agreement with Apothecanna, which, on closing, will have an immediate impact on HempFusion’s revenue while significantly bolstering our distribution and eCommerce platforms,” HempFusion cofounder and CEO Jason Mitchell, N.D., stated in the announcement. “We look forward to working to close the transaction as soon as possible.” Ecommerce accounts for about 50 percent Apothecanna’s revenues, driving more than 17,000 average monthly sessions, and nearly $2 million in gross sales per year with a 76 percent gross margin. On May 12, HempFusion also announced a recent purchase order for more than $200,000 of its branded products signals the revival of international sales following the difficulties posed by the COVID pandemic for foreign transactions during the past year (https://ibn.fm/Lh7nF). The unnamed multi-billion-dollar distribution company that placed the purchase order has not ordered anything from HempFusion in over a year. Because of the two companies’ historical relationship over most of the last decade, HempFusion had expected the other company, which is based in Dubai, to place orders for $800,000 worth of product in 2020 and $1 million worth of product this year. So HempFusion is “excited to see this early indication that business on a global scale is starting to move in the right direction,” HempFusion Head of International Development Patrick Bucaro stated in the announcement. HempFusion has over a year of working capital and no plans for further financings at this time. Prior to establishing the acquisition agreement with APCNA Holdings, the company stated its products are sold in about 4,000 retail locations in all 50 U.S. states utilizing 45 brokers and sales representatives in the natural products industry and another 55 in the doctor/practitioner market, conventional food, drug, mass and convenience (“FDMC”) market and international markets. HempFusion is also listed in Canada on the Toronto Securities Exchange (“TSX”) and has expectations of entering India, Ireland, and the United Kingdom in the near future. For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics
• Cybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trials
• Ketamine is a dissociative injected anesthetic that blocks sensory perception

Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the Kernel Flow technology; the study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/BW1Jn). “We still have much to learn about what is occurring in the brain during a psychedelic experience,” said Cybin CEO Doug Drysdale. “This first-of-its-kind, Cybin-sponsored study using the Kernel Flow device aims to expand our physiological understanding of psychedelic pharmacotherapy. We are excited to be part of this pioneering journey with our partners at Kernel.” Cybin announced a partnership with Kernel earlier this year. The two companies are working together to leverage Kernel’s proprietary Kernel Flow device for psychedelic-based studies and clinical trials. The Kernel Flow device is the first commercially scalable time-domain near-infrared spectroscopy (TD-fNIRS) system in history. The device uses quantitative neuroimaging technology that measures brain activity in real time when users wear the device during psychedelic treatments. According to Cybin, Kernel Flow uses pulsed light to increase measured brain information. In contrast with electroencephalography (“EEG”) electrodes, which typically require gel on the head, or functional magnetic resonance imaging (“fMRI”) studies, which require a participant to lie in a scanner, the Flow device is a wearable helmet. The device has potential for broad use in neuroscientific or physiological studies of brain activity during psychedelic use; little direct neuroimaging research of psychedelic effects, in vivo, have been attempted until now, and that research has never been done with a wearable device. The study will use the device to study ketamine, a dissociative injected anesthetic that blocks sensory perception and has been available by prescription in the United States since the 1970s for human and veterinary uses (https://ibn.fm/uv5Zk). A form of ketamine has been approved for treatment-resistant depression and is approved for use in depressed patients with acute suicidal ideation or behavior. In the United States, ketamine is a class III scheduled drug and is approved for use in hospitals and other medical settings as an anesthetic. “Psychedelics have shown great promise for mental health and wellness, and Kernel’s collaboration with Cybin has the promise of offering increased scientific rigor for their development,” said Kernel founder and CEO Bryan Johnson. Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDA
• Bladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and management
• Imagin Medical plans to complete its proprietary i/Blue Imaging System in 2022

The National Cancer Institute (“NCI”) lists urinary bladder cancer as the sixth most prevalent form of cancer in the United States. In 2021, NCI estimates that the total number of new bladder cancer cases will total 83,730, with deaths estimated at 17,200. The recurrence rate for bladder cancer is greater than 50%, making it one of the highest recurrence rates of all cancers. Approximately 724,000 people live in fear that their cancer will return (https://ibn.fm/BST5x). Continuous monitoring of patients who might suffer a recurrence of bladder cancer will generate over 1,000,000 physician consultations per year. These visits add to the $4 billion in costs for bladder cancer management. It is estimated that 25% more tumors are removed using blue light cystoscopy (“BLC”), a more recent technology, that works in conjunction with white light, reducing recurrence and monitoring expenses over the long term. However, the challenges for surgeons with current BLC technology include locating the exact position of the cancer within the bladder. Currently, the surgeon needs to switch back and forth between white light and blue light images, yet still does not have precise visualization. This is one reason that hospitals and doctors have been slow to adopt BLC. Imagin Medical (CSE: IME) (OTCQB: IMEXF) is currently working closely with manufacturing partner Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer, on the company’s proprietary i/Blue Imaging System once per article – it is already above. Their innovative technology will have the ability to display white and blue light images side-by-side simultaneously, providing better visualization and allowing surgeons greater ability to detect and remove cancerous tumors from the bladder. In addition, the technology will adapt to most endoscopes used in the operating room today, enabling easier and cost-effective adoption without requiring hospitals and doctor’s offices to replace their current equipment. In a recent press release, Imagin Medical announced that the i/Blue Imaging System is on target for demonstration during private meetings at the American Urology Association (“AUA”) annual meeting scheduled for early September. The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems and feedback from preliminary meetings with the FDA (https://ibn.fm/XscrI). Additional testing and specification development was focused on the contrast agent-induced fluorescence and the ability to replicate the clinical observations in bench-level settings. The sensitivity of the system can now be demonstrated with the established testing methods. “We’re creating the potential for additional IP that will make the i/Blue Imaging System unique and innovative and strengthen the demand for blue light cystoscopy,” said Jim Hutchens, Imagin’s president and CEO. “Patients have been hearing about the superiority of blue light over white light to identify bladder cancer tumors and are searching for facilities that provide it.” Although the primary focus of Imagin Medical is bladder cancer, the company intends to expand the i/Blue Imaging System technology for use in other minimally invasive surgical procedures. The i/Blue Imaging System is expected to be completed in 2022. For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021
• As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program
• Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics

Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases. As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic substance – in order to develop clinical-stage compounds for diseases with high unmet medical needs, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is the perfect candidate to participate in psychedelics events. In a recent press release (https://ibn.fm/Z8Ify), Tryp announced it would present at one such event: the virtual Psychedelics in Psychiatry and Beyond Conference slated for Thursday, June 17, 2021, and sponsored by H.C. Wainwright & Co., one of America’s oldest and most trusted investment banks focused on equity research and capital market activity. As part of Tryp’s presentation to be made available on-demand from 7 a.m. EDT on the day of the conference, Chairman and CEO Greg McKee will offer insight into the company’s business as well as its research-backed pipeline, including the proprietary Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program. The PFN program is Tryp’s psychedelics-centered drug development platform targeting certain neuropsychiatric disorders, including fibromyalgia, chronic pain, and eating disorders. The program’s lead drug candidate, TRP-8802, is expected to proceed directly to Phase 2a clinical trials as Tryp intends to leverage existing preclinical and clinical data from the expansive body of research on the active pharmaceutical ingredients in TRP-8802. This approach is expected to accelerate the drug development process toward ultimate approval by the US Food and Drug Administration (“FDA”). The company intends to further expand research into other indications for psilocybin that, up until this point, have received little attention from pharmaceutical companies. By collaborating with multiple academic institutions and leading principal investigators, Tryp expects to develop new novel treatments, thereby addressing the significant unmet medical needs. Designed for public and private companies, industry executives, business development executives, venture capitalists, private equity firms, and institutional investors, the conference will feature company presentations, one-on-one investor meetings, and networking opportunities. Attendees should look forward to gaining a deep understanding of psychedelics and the future of this vital class of compounds in psychiatric applications as well as other uses. Tryp will present alongside other leading pharmaceutical companies currently building a robust R&D pipeline of psychedelic-assisted therapeutics. These include Mindset Pharma Inc. (https://ibn.fm/kUTKb) and Mydecine Innovations Group (https://ibn.fm/178sr), among others. To register for the event, attendees can use the following link: https://ibn.fm/5uuv1 For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• New report cites new management, very good customer ratings and record revenue in initiating CHAL coverage
• Chalice Brands acquisition of Homegrown Oregon also noted
• CHAL’s consistent increase in financial numbers key to BUY rating as well

A recent Fundamental Research Corp. report has initiated coverage of Chalice Brands (CSE: CHAL) (OTCQB: CHALF) with a BUY rating and a fair value estimate of C$2.46 (https://ibn.fm/W7HfD). CHAL closed at C$1.37 on June 8, 2021.  Chalice is a leader in retail, marketing and craft cultivation supported by fully integrated processing and distribution. “New management has demonstrated their ability by significantly growing the company’s revenue and margins in 2020,” the Fundamental Research Corp. report stated. “Another testimonial for the team is that all of their stores have very good customer ratings. We are expecting record revenue in 2021, driven by organic growth and the recent acquisition. We are also expecting a bump in valuations of U.S. cannabis players as the sector moves closer to federal legalization.” As a basis for its BUY rating, the report noted the management overhaul, which includes key team members from Fortune 25 companies and brings experiences from companies such as Microsoft (NASDAQ: MSFT), Kraft Foods (NASDAQ: KHC), Dell (NYSE: DELL), Merrill Lynch and PepsiCo (NASDAQ: PEP) to Chalice. The report also cited the company’s seven retail stores in Oregon, which accounted for 90% of the company’s 2020 revenues. In addition, “the company recently announced it acquired a five-store retail chain, ‘Homegrown Oregon,’ valued at US$9.75M,” the report observed. “Homegrown had $2.7M in revenue and $364K in adjusted EBITDA for the quarter ended March 31, 2021, per management. The implied EV/R of the transaction is 0.9x vs the peer group average of 4x.” The report also pointed to CHAL’s 2020 revenues, which were $22 million, a 39% year-over-year increase through organic growth, as well as the fact that its Q4 2020 numbers noted positive EBITDA. “In Q1 2021, revenue increased 18% YoY to $5.5M,” the report continued. “EBITDA was positive in Q1 2021 as well. In 2021, CHAL raised C$13.75M through private placements.” Finally, the report noted that both the Oregon and California cannabis market saw record sales in 2020, with Oregon reporting $1.1 billion in sales and California posting $4.4 billion in sales, a year-over-year increase of 38% and 57% respectively. “U.S.-based cannabis stocks are currently trading at a discount over their Canadian peers,” the report stated. “We expect this trend to change with federal legalization in the U.S. and anticipate CHAL to directly benefit. We are expecting record revenue for CHAL in 2021. Management is targeting to capture 5% of the Oregon retail cannabis market, which we believe is a feasible target.” Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon. The Company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California. For more information, visit the company’s website at www.ChaliceBrandsLtd.com. NOTE TO INVESTORS: The latest news and updates relating to CHALF are available in the company’s newsroom at https://ibn.fm/CHALF

• Americans pay more for prescription drugs than any other nation in the world; prices keep increasing
• Patients pay about 14% of prescription drug costs out of pockets; around 20% report not being able to complete a prescribed course of medicine due to costs
• UME’s committed to providing consumers better access to the healthcare they need; its Medication Management App features GoodRx in-built functionality enabling them to view discount prices and coupons

United Medical Equipment Business Solutions Network (“UME”) has developed the Medication Management App with twelve different functionalities within the convenience of one application, with the newest addition of GoodRX — a feature that allows users to save money on prescription drugs. Prescription drug spending in the US eclipse that in all other countries — on average $1,200 per person per year — mainly due to high prices of brand-name drugs, which have been increasing faster than the consumer price index (https://ibn.fm/4wdP7). Market exclusivity protected by monopoly rights and patents allows manufacturers to set high drug prices. The prices usually fall after the exclusivity period ends and generic drugs become available, but access to them may be postponed by numerous business and legal tactics. Another contributing factor to high medication spending is doctors prescribing more expensive choices when cheaper alternatives are available. Although high prices are often justified by the high cost of drug research and development, there is no evidence to support this. Instead, prescription drugs are often priced based on what the market will bear. As patients pay about 14% of prescription drug costs out of their own pockets, many are not able to afford the medication bills. A survey found that 20% of US adults could not complete a prescribed course of medicine because of cost, compared to 10% in Germany, Canada, and Australia. UME’s Medication Management App enables users to make quick, well-informed, and potentially lifesaving decision making on the go. The app features an integrated GoodRx function that allows users to view discount prices and coupons while managing medications all within the app. GoodRx, a company allowing users to compare drug prices and find coupons at over 60,000 pharmacies across the US, enables consumers to shop around for prescription drugs and lower their medication costs. Around 20 million people visit GoodRx every month, and over the past decade, the app has helped more than 18 million patients pay for a prescription medication they otherwise would not have been able to afford, saving them around $30 billion to date (https://ibn.fm/3Yfyo). With the help of the GoodRx in-built feature, the UME’s Medication Management App users can compare prices between pharmacies, access free coupons for their prescriptions, and show the coupon to the pharmacist when picking up the prescription — all without ever leaving the app. As US drug manufacturers remain unregulated, which means they can set any price they believe the market will bear for a given drug, the out-of-pocket costs for patients will likely continue to rise. UME strives to be the leading provider of high-quality, reliable, and transparent information and resources for consumers, helping them access the high-quality, affordable healthcare they need. For more information, visit the company’s website at www.UnitedMedSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• Most extensive research to date reports significant neurological problems in patients who suffered from so-called long-haul COVID-19
• Neurological issues range from mild to more severe such as cognitive impairment, which affects around 20% of these patients
• BRSF appears poised to be part of the solution as long-haulers need monitoring so that doctors can assess if they have neurological disorders

The neurological and psychiatric aftermath of COVID-19 has been reported, but adequately assessing the effects of the disease on brain health still remains a challenge. A new preprint analysis, representing one of the most extensive studies of neuropsychiatric symptoms among COVID-19 long-haulers, reports that patients who have been sick with COVID-19 for more than three weeks experience cognitive impairment at least six months after the infection (https://ibn.fm/OSDQx). Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is poised to provide brain monitoring capabilities to enable clinicians to study the brain wave activity of patients with neurological conditions. So-called long COVID has gained momentum over the past year as some patients reported persistent neurological and psychiatric manifestations after their initial infection. The extensive research studied nearly 19,000 adult patients across 51 studies, discussing evidence indicating a potential relationship between COVID-19 and persistent neurological problems. These problems could range from milder symptoms, including headaches, loss of sense of smell and taste, and fatigue, to more severe conditions, including sleep disorders, pain, and cognitive impairment such as brain fog leading to memory loss or difficulty concentrating or making decisions. The study found that brain fog affects 20% of Coronavirus long-haulers, while 27% of them reported insomnia, and 24% reported fatigue, both of which researchers believe could stem from neurological issues, although that might not be the only possible cause. Brain fog can have varying impacts on patients; for some, it may be life-altering, while for others can be a minor inconvenience. However, diagnosing long-term COVID-19 symptoms remains a challenge as doctors are still learning the underlying mechanisms of how the virus works. For example, without knowing how long these neurological symptoms last, doctors are not able to classify them as neurological disorders or even chronic illnesses. The researchers conclude that doctors will need to track long-haulers to decipher whether they have neurological disorders after they suffered and survived Coronavirus infection. As a growing body of research indicates, the long-term outlook for COVID-19 patients is still uncertain. Long haul Covid-19 survivors will need ongoing medical help to track and manage the long-term impact of the virus on their health, including brain health. That’s where Brain Scientific’s unique technology can help. The Company has developed NeuroEEG(TM), a portable, wireless device that can record and display the patient’s electrical brain activity that works together with the NeuroCap(TM) — a hospital-grade disposable EEG headset that comes in sizes for adults and pediatric patients.  Brain Scientific is working on developing another revolutionary technology — Brain E-Tattoo(TM), a minimally invasive four-channel implant or imprint tattoo designed for long-term brain wave activity monitoring even beyond the clinical setting. It can provide access to long-term neurological studies, potentially helping identify root neurological problems. More than a year into the pandemic, it remains a challenge to understand the immediate effect of the virus on brain health, with no definite answer regarding the long-term impact either (https://ibn.fm/xNJLl). The scientific world is only starting to truly grasp the effect of COVID-19 on the brain. Brain Scientific appears poised to be a key player providing unparalleled technology that will potentially contribute to providing answers to the most pressing issues in the modern brain diagnostics space. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• HempFusion Wellness Inc. offers a full line of CBD products for consumers and medical professionals, via subsidiaries Probulin Probiotics, HF Labs, and Biome Research
• Probulin finished 2020 as one of the fastest growing probiotic brand in the United States according to Spins Data
• Brightfield Group named HempFusion the #2 most recognized CBD brand in America
• Company’s visibility further increased by recent participation in a groundbreaking ValidCare study on CBD and human safety
• Global CBD market is expected to grow from $2.8 billion in 2020 to $13.4 billion in 2028

HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO), a Denver-based cannabidiol (“CBD”) company focused on utilizing the power of whole-food hemp nutrition for health and wellness, is strategically positioned to leverage its rich product offering and industry knowledge and awareness to capitalize on exceptional growth opportunities expected to emerge on the fast-expanding CBD market. With the increasing acceptance of CBD for various health benefits and wellness purposes, the global cannabidiol (“CBD”) market size is growing exponentially. The industry was valued at $2.8 billion in 2020 and from 2021 to 2028, it is expected to grow at a CAGR of 21.2%, resulting in a revenue forecast of $13.4 billion in 2028 (https://ibn.fm/4mb3h). Offering product lines that span multiple product categories, ranging from capsules and tinctures to OTC topicals and condition-specific OTC topicals, the company has the potential capture a considerable slice of this market. Another expanding market HempFusion can capitalize on is the probiotics industry, via 100% wholly-owned subsidiary Probulin Probiotics. Probulin addresses a wide range of consumer needs, including daily care, women’s health, total care, and children’s products. Focused on the medical / professional industry, subsidiaries HF Labs and Biome Research product lines are directed toward doctors and practitioners, as well as catering to hospitals, compounding pharmacies, and free-standing dispensaries. HempFusion has estimated the target market size to include 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, potentially opening new growth opportunities for the company. The anticipated growth comes on the heels of increased visibility in the industry following participation in a high-profile CBD study. HempFusion was one of 12 CBD companies selected to participate in groundbreaking research by ValidCare regarding CBD and human safety. ValidCare designed the study to address previous questions the FDA brought forward regarding the use of CBD products. As a part of this study, HempFusion was included in this human trials to help determine if the daily use of full-spectrum CBD or CBD isolate products impacted the human liver (https://ibn.fm/FxZ3h). Results released in March 2021 show validation for the use of CBD products and no liver toxicity, as detailed by HempFusion co-founder and CEO Jason Mitchell, ND, in a press release. “We believe this is a pivotal step forward for the CBD industry, and we look forward to continuing to find ways to provide consumers with safe and quality products,” Dr. Mitchell said. “When specifically looking at how our products performed in the study, having no liver toxicity only bolsters what we have always stated about our products. We believe they are safe,” Dr. Mitchell continued. After a recent decline in stock price, Mitchell again took to the media outlets, underlining that the company is transparent with investors and that all material information is available. He assured the public and investors that the recent developments were not caused by an “undisclosed development” within the company, and reiterated that HempFusion is in the strongest position it has ever been for where the CBD industry is heading and what new regulatory development loom on the horizon. (https://ibn.fm/kkO0Q). “We believe the Company is in the strongest position it has ever been with significant partnerships, developments, new distributors, and international channels deep in development, including a significant sales pipeline, consumers returning to stores, multiple international expansion initiatives, and a robust balance sheet, including a strong cash position of approximately US$9.3 million as of December 31, 2020, in addition to the closing of the Company’s US$17 million initial public offering on January 6, 2021,” Dr. Mitchell explained. HempFusion’s position seems to be reinforced by recent events, including it being named the second in the U.S. for CBD Brand Awareness by the Brightfield Group, and Probulin finishing 2020 as one of the fastest-growing probiotic brand out of the Top 15 in the U.S., according to SPINS. The company remains excited about the future and its global reach, which is anticipated to expand exponentially following entry into the Asian through Tmall Global, after receiving conditional approval. The approval gives HempFusion the potential to reach more than 750 million new consumers. For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• Reported on the therapeutic benefit of munchies for nausea and vomiting
• Recorded over 14,500 sessions from patients seeking relief from nausea
• Munchies are a medical benefit for those going through chemotherapy or diagnosed with cachexia, also known as a wasting disorder

RYAH Group (CSE: RYAH), the leading data technology company in plant-based medicine, collects data through its IoT dose-measuring devices and AI analytics. Recently the company reported on The Therapeutic Benefit of the Munchies for Nausea and Vomiting. The full article can be found at https://ibn.fm/mgkad. RYAH is uniquely positioned to collect essential data that can lead to more personalized and targeted care within the health industry. The Company partners with doctors, researchers, product suppliers, and retailers to place its top-rated apps, dose-controlled devices and services into the hands of patients and consumers. *The AI platform aggregates and correlates HIPAA-compliant dosing data from seed to consumption, allowing the company to run in-depth analytical reports. These reports help identify trends and consumer outcomes. Cannabis has always carried a reputation for causing a case of the “munchies.” While some might find this side effect bothersome, others turn to it for that exact reason. Since 2018, RYAH has recorded over 14,500 sessions with patients seeking relief from nausea with medical cannabis. Currently, cannabis is a patient-driven choice in treating nausea, vomiting, and appetite loss. Of all the conditions that patients turn to medical cannabis for, nausea and vomiting continue to be two of the most socially and legally accepted. It is common for those going through chemotherapy to seek relief and also used by those who have cachexia, a wasting disorder that causes extreme weight loss, nausea and vomiting. As evidence builds through various clinical studies, cannabinoid therapy may soon become a common doctor-recommended prescription rather than merely a patient’s request. RYAH first developed and commercialized its smart inhaler in 2018. Since then, it has developed a complete IoT device and data analytics platform with multiple delivery mechanisms that include the Smart-Inhaler, Smart Transdermal Patch, and the Smart Pen. The company has also developed data-driven platforms for doctors and for patients. RYAH MD is a remote and interactive patient-doctor collaboration and dosing administration platform that allows for real-time monitoring, appointment booking, doctor-patient video calls, science-based strain recommendations and more. For the patient and end-user, there is the PotBotApp. This medical cannabis education mobile app creates a personalized and data-driven resource of potential product matches for the user’s ailments and efficacy goals. RYAH is rapidly expanding and actively looking for partnerships as it takes its data-driven technology and plant-based medicine global. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• Nextech AR Solutions is the leading provider of human holograms, which it expects will revolutionize the way that business, education, and society interact
• The global COVID pandemic has driven remote work solutions to satisfy economic concerns, and as the health crisis eases in many regions Nextech anticipates remote AR technologies will continue to remain popular
• Nextech recently announced its selection for telecommunications giant Ericsson’s Startup 5G program for developing tech innovation and advancing 5G networks using Teleportation Technology at Scale
• Nextech and MSFT Team up to Co-Sell EdTechX to help professors deliver digital AR presentations to remote students, using Nextech HoloX and Microsoft Azure

Across the country, Americans are celebrating reports of reduced infections under the global pandemic that has altered lifestyles during the past year. As health agencies continue to make vaccines available against the COVID virus, relaxing warnings against group gatherings for those who are vaccinated or taking other precautions, working populations are using lessons learned during the pandemic to re-engage the job market with a new vision of what life should be like. Remote Work is here to stay: One recent study captured the mood of the country when it noted that 61 percent of parents want jobs that allow them to work remotely full-time without in-office requirements, and that 62 percent of those parents would quit their current job if the pandemic-driven option to work remotely is eliminated (https://ibn.fm/W9jCY). The study, and others like it (https://ibn.fm/Fb782), portend an evolving workplace in which technology will be a key driver of newfound freedom to move the economy while removing oneself from the economic engine to pursue personal priorities (https://ibn.fm/tKe7Y). Technology will be a big beneficiary of remote work: The visionaries at augmented reality pioneer Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) are building their brand on the promise of helping people make life seem a little more real, by allowing work to be a little less so through AR capabilities. As 5G network infrastructures begin to move into place, Nextech AR Solutions is finding a ready market for its virtual experiences that employ digital human holograms streamed into users’ own environments. The holograms can be world leaders speaking on matters of policy in a viewer’s own home, or a medical professional providing instruction on healthcare and medication, or simply birthday wishes sent by loved ones from far-flung corners of the globe. Business and school whiteboarding can move meetings holographically out of the office and into remote work sites as well. Earlier this month, Nextech announced the launch of its EdTechX solution built on Microsoft Azure, which enables educational institutions to transform learning forums into evolved virtual experiences (https://ibn.fm/1XOki). 5G will provide more powerful AR experiences as the evolved networks become more widely available. Telecommunications giant Ericsson (NASDAQ: ERIC), the first company to bring 5G to four continents, is at the forefront of the dawning 5G, IoT, edge computing and cloud network infrastructure era. And Nextech AR recently announced that it is one of the few companies selected to be part of the Ericsson Startup 5G program, which helps members launch innovative technology to accelerate the successful commercialization and monetization of 5G. The program will provide participants with exposure in major technology events while connecting them with partners around the world to help them grow their business and share strategic know-how, according to a June 3 news release about Nextech’s selection (https://ibn.fm/sh9e1). “Being part of the program opens up new opportunities working with one of the many customers Ericsson has in the telecom and enterprise space to drive 5G innovation and also seek Ericsson’s help to scale our augmented reality hologram creator platform AiR Show,” Nextech AR CEO Evan Gappelberg stated. “Another benefit of this partnership is that we are able to get early access to the latest network innovations such as 5G or MEC (Mobile Edge Computing) to evaluate how these emerging technologies can be utilized for a better user experience.” Nextech AR plans to introduce a live demonstration of its human hologram capabilities in the company’s Sweden lab, where visitors can experience how live sports, digital advertising, and mobile shopping will be augmented by immersive AR. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF